公开(公告)号：US20240343828A1

公开(公告)日：2024-10-17

申请号：US18595079

申请日：2024-03-04

申请人： Northwestern University

发明人： Ankit Bharat ,  Yuanqing Yan ,  GR Scott Budinger ,  Ali Shilatifard

IPC分类号： C07K16/38 ,  A61K31/4706 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61P11/00 ,  C07K16/28 ,  C12N15/113

CPC分类号： C07K16/38 ,  A61K31/4706 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61P11/00 ,  C07K16/2863 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141

摘要： Provided herein is a method of treating or preventing acute or chronic lung disease in a subject, comprising administering an agent that modulates the expression of Serine Protease Inhibitor Kazal-type 1 (SPINK1) to the subject.

公开(公告)号：US12109253B2

公开(公告)日：2024-10-08

申请号：US17426756

申请日：2020-01-30

申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

发明人： Wenn-Chyau Lee ,  Laurent Renia

IPC分类号： A61K38/36 ,  A61K31/137 ,  A61K31/155 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/635 ,  A61K31/65 ,  A61K38/18 ,  A61P33/06

CPC分类号： A61K38/36 ,  A61K31/137 ,  A61K31/155 ,  A61K31/357 ,  A61K31/366 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/635 ,  A61K31/65 ,  A61K38/18 ,  A61P33/06

摘要： The invention relates to a composition comprising insulin growth factor binding protein 7 (IGFBP7) for treating malaria or reducing the phenomenon of IRB C-endothelial cytoadherence. The composition can further comprise Von Willebrand Factor (VWF) and/or thrombospondin-1 (TSP-1). The composition can also be used as an adjunct therapeutic agent alongside other anti-malarial drugs.

公开(公告)号：US20240307487A1

公开(公告)日：2024-09-19

申请号：US18735027

申请日：2024-06-05

申请人： The University of Hong Kong

发明人： Hanjun Zhao ,  Kwok-Yung Yuen

IPC分类号： A61K38/17 ,  A61K31/4045 ,  A61K31/4706 ,  A61P31/14 ,  A61P31/16

CPC分类号： A61K38/1729 ,  A61K31/4045 ,  A61K31/4706 ,  A61P31/14 ,  A61P31/16

摘要： Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The disclosed antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus.

公开(公告)号：US20240285581A1

公开(公告)日：2024-08-29

申请号：US18629099

申请日：2024-04-08

申请人： Boulder BioScience LLC

发明人： Michael A. Zeligs ,  Irwin C. Jacobs

IPC分类号： A61K31/404 ,  A61K9/00 ,  A61K31/122 ,  A61K31/137 ,  A61K31/203 ,  A61K31/23 ,  A61K31/4045 ,  A61K31/41 ,  A61K31/4427 ,  A61K31/451 ,  A61K31/4706 ,  A61K31/51 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/704 ,  A61K38/46 ,  A61K38/48 ,  A61K39/395 ,  A61P7/02 ,  A61P9/10

CPC分类号： A61K31/404 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/122 ,  A61K31/137 ,  A61K31/203 ,  A61K31/23 ,  A61K31/4045 ,  A61K31/41 ,  A61K31/4427 ,  A61K31/451 ,  A61K31/4706 ,  A61K31/51 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/704 ,  A61K38/465 ,  A61K38/482 ,  A61K39/3955 ,  A61P7/02 ,  A61P9/10

摘要： Provided herein are methods of enhancing mechanical thrombectomy during endovascular therapy for acute thrombosis using 3,3′-diindolylmethane.

公开(公告)号：US20240270855A1

公开(公告)日：2024-08-15

申请号：US18565581

申请日：2022-06-02

申请人： Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud

发明人： José Henrique Veiga Fernandes ,  Ana Filipa Ribeiro Cardoso

IPC分类号： C07K16/28 ,  A61K31/137 ,  A61K31/27 ,  A61K31/44 ,  A61K31/4704 ,  A61K31/4706 ,  A61K31/538 ,  A61K31/55 ,  A61K38/17 ,  A61K38/18 ,  A61K39/395 ,  A61P3/04

CPC分类号： C07K16/2863 ,  A61K31/137 ,  A61K31/27 ,  A61K31/44 ,  A61K31/4704 ,  A61K31/4706 ,  A61K31/538 ,  A61K31/55 ,  A61K38/179 ,  A61K38/185 ,  A61K39/3955 ,  A61P3/04

摘要： The present disclosure provides a neuro-mesenchyme signaling axis that controls group 2 innate lymphoid cells (ILC2s), adipose tissue physiology, metabolism, and obesity. This signaling axis includes ILC2s with rearranged during transfection (RET) receptor, mesenchymal stromal cells (MSCs) with beta-2 adrenergic receptor (ADRB2), and high-order brain areas including the paraventricular nucleus of the hypothalamus (PVH).

公开(公告)号：US20240269128A1

公开(公告)日：2024-08-15

申请号：US18627191

申请日：2024-04-04

申请人： THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human

发明人： Madhav Thambisetty ,  Myriam Gorospe ,  Carlos Anerillas

IPC分类号： A61K31/4706 ,  A61K31/18 ,  A61K31/404 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/506 ,  A61K31/575 ,  A61K31/7024 ,  A61P25/28

CPC分类号： A61K31/4706 ,  A61K31/18 ,  A61K31/404 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/506 ,  A61K31/575 ,  A61K31/7024 ,  A61P25/28

摘要： A subject is administered an amount of an active agent effective to at least partially normalize an aberrant level of one or more indicators, wherein the indicators comprise extracellular amyloid beta concentration, tau phosphorylation, neuroinflammation, or any combination thereof. The subject may be diagnosed with Alzheimer's disease or may be identified as being at risk of developing Alzheimer's disease.

公开(公告)号：US12059499B2

公开(公告)日：2024-08-13

申请号：US17313334

申请日：2021-05-06

申请人： PLUMB PHARMACEUTICALS, INC.

发明人： Timothy D. Heath ,  Lisa Ann Krugner-Higby ,  Amy Lautenbach

IPC分类号： A61K9/127 ,  A61K31/4706 ,  A61K31/485 ,  A61K31/65

CPC分类号： A61K9/1278 ,  A61K9/127 ,  A61K31/4706 ,  A61K31/485 ,  A61K31/65 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

摘要： Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.

公开(公告)号：US20240238272A1

公开(公告)日：2024-07-18

申请号：US18561712

申请日：2022-06-01

申请人： Genovate Biotechnology Co. Ltd.

发明人： Jen Chen ,  Chia-Chen Chu

IPC分类号： A61K31/4706 ,  A61P7/02

CPC分类号： A61K31/4706 ,  A61P7/02

摘要： A method for treating antiphospholipid syndrome by administering to a patient a pharmaceutical composition that contains S-(+)-hydroxychloroquine and a pharmaceutically acceptable excipient. The pharmaceutical composition is substantially free of R-(−)-hydroxychloroquine.

公开(公告)号：US11883491B2

公开(公告)日：2024-01-30

申请号：US16610170

申请日：2018-04-30

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： Jian Zuo ,  Fei Zheng ,  Tetsuji Yamashita ,  Zoe Kellard ,  Tal Teitz ,  Jaeki Min ,  Taosheng Chen

IPC分类号： A61K31/18 ,  A61K31/422 ,  A61K31/44 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/58 ,  A61K45/06 ,  A61K39/395 ,  A61P27/16 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/713 ,  A61K38/17

CPC分类号： A61K39/3955 ,  A61K31/18 ,  A61K31/422 ,  A61K31/44 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/58 ,  A61K31/713 ,  A61K38/1709 ,  A61K45/06 ,  A61P27/16

摘要： Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.

公开(公告)号：US20230357367A1

公开(公告)日：2023-11-09

申请号：US18314091

申请日：2023-05-08

申请人： Generate Biomedicines, Inc.

发明人： Francesco Borriello ,  Alexis Hiram Ramos

IPC分类号： C07K16/10 ,  A61K45/06 ,  A61P31/14 ,  A61K31/7052 ,  A61K31/4706 ,  A61K39/215 ,  A61K31/7068 ,  A61K31/675 ,  A61K31/4965 ,  A61K31/215 ,  A61K31/13 ,  A61K31/45 ,  A61K31/7088

CPC分类号： C07K16/1003 ,  A61K45/06 ,  A61P31/14 ,  A61K31/7052 ,  A61K31/4706 ,  A61K39/215 ,  A61K31/7068 ,  A61K31/675 ,  A61K31/4965 ,  A61K31/215 ,  A61K31/13 ,  A61K31/45 ,  A61K31/7088 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2317/92 ,  C07K2317/34 ,  C07K2317/94 ,  A61K2039/505

摘要： The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).